A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of single ascending doses of BT051 in healthy male or female volunteers aged 18 to \<50 years. A total of 50 subjects will be randomized to receive a single oral dose of BT051 or matching placebo in a ratio of 4 active:1 placebo in 5 ascending dose cohorts (10 subjects per cohort) at active dose levels of 100mg, 300mg, 700mg, 1500mg or 3500mg. The study Safety Review Committee (SRC) will evaluate if any dose-limiting adverse events (AEs) occurred in a cohort through Day 3, as well as review cumulative safety data for all previous cohorts and any available pharmacokinetic (PK) data before proceeding to dosing in the next cohort.

Key facts

Study ID

NCT05103878

Run by

Bacainn Therapeutics, Inc.

People needed

50

Starts

2020-06-24

Expected to finish

2020-11-13

Last updated by the study team

2022-03-28

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must meet all the following criteria to be considered eligible to participate in the study:
• Male or female subjects age ≥18 years and <50 years
• In good health with no clinically significant abnormalities as determined by medical history, physical exam, and laboratory values
• Able and willing to provide written informed consent
• Be able to understand the study procedures and agree to participate in the study
• For male subjects, be surgically sterile or agree to use an appropriate method of contraception (i.e., condom) or have a female sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive with a barrier method approved and deemed highly effective by the United States Food and Drug Administration (FDA) through 30 days after the dose of study drug
• For female subjects of childbearing potential, be using an insertable, injectable, or transdermal hormonal contraceptive, or combination oral contraceptive with a barrier method approved and deemed highly effective by the FDA through 30 days after the dose of study drug and have negative results on pregnancy tests done at Screening and on Day -1. NOTE: women who are surgically sterile or postmenopausal (i.e., no menses for at least 2 years or documented by follicle stimulating hormone) are also eligible to participate.
• Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements, including confinement in the clinical unit through Day 3
• Body mass index (BMI) >18.5 and <32.0 kg/m\^2
• Ability to fast for at least 10 hours and consume standard meals
• Willingness to discontinue concomitant medications

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from participating in the study:
• Pregnant, breast feeding, or seeking pregnancy while on study
• Have, as determined by the investigator, a history or clinical manifestations of significant neurologic, renal, hepatic, hematologic, cardiac, pulmonary, metabolic, endocrine, psychiatric, gastrointestinal (GI) disorders (including infectious, ischemic, inflammatory bowel disease, irritable bowel syndrome, known lactose intolerance, or immunological diseases) or other condition that would preclude participation in the study
• Have a history of a malignancy (or active malignancy), with the exception of subjects with basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix who have been treated and cured
• Have had any symptoms of cold, flu, or febrile illness within 2 weeks prior to dosing
• Have received any live attenuated vaccine within 30 days of dosing
• Have received cyclosporine A within the last 1 month, including Restasis® (cyclosporine ophthalmic emulsion) for dry eye syndrome or any other cyclosporine ophthalmic preparation
• Participation in a clinical trial of an investigational drug or medical device within 30 days before Screening
• In the opinion of the Investigator, unable to comply with the study protocol
• Have a history of alcoholism or illicit drug use within 2 years before the scheduled dose of study drug
• A positive test result for any of the following: human immunodeficiency virus (HIV), hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV) antibody, drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), and alcohol.
• Have donated more than 500 mL of blood within 60 days before the scheduled dose of study drug
• Have taken prescription medications within 5 half-lives of the specific substance (or, if half-life is not known, within 48 hours) before the scheduled administration of study drug
• Have taken over-the-counter medication or supplements, including nutritional supplements, stool softeners (e.g., Miralax), or colon preparations within 7 days before dosing
• History of any hypersensitivity or allergic reaction to cyclosporine
• History of GI surgery or any part of GI tract removed excluding appendectomy and cholecystectomy
• Use of tobacco or marijuana products within the previous 6 months

Where it is running

• Spaulding Clinical Research, LLC — West Bend, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.